vendredi 26 avril 2013

Press Review (April 27, 2013) – Revue de presse (27 avril 2013)

Cancer Physicians Attack High Drug Costs
With the cost of some lifesaving cancer drugs exceeding $100,000 a year, more than 100 influential cancer specialists from around the world have taken the unusual step of banding together in hopes of persuading some leading pharmaceutical companies to bring prices down.
By Andrew Pollack. In The New York Times    

Skin Cancer Linked to Higher Risk of Other Cancers
There’s another reason for those at risk of skin cancer to stay vigilant about protecting their health. Men and women with a history of non-melanoma skin cancer are at a higher risk of developing breast and lung cancers in addition to melanoma, compared to people without a skin cancer history
By Alexandra Sifferlin. In TIME

Cancer survival rates improve but most people remain financially exposed
Medical advance means more people diagnosed with cancer are surviving for longer, according to new figures from the Office for National Statistics (ONS), but relatively few people have any financial protection in place against the risk of living with reduced earning power.
By Ian Cowie. In (blog)           

Chernobyl Follow-Up Study Finds High Survival Rate Among Young Thyroid Cancer Patients
More than a quarter of a century after the Chernobyl nuclear disaster, many children and teenagers who developed thyroid cancer due to radiation are in complete or near remission, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
In Science Daily (press release)                       

Adrenalectomy for Metastases Benefits Renal-Cancer Patients
Surgical removal of adrenal metastases can offer long-term survival to selected cancer patients — most notably those with renal-cell carcinoma — the results of a large multicenter study indicate.
By Miriam E. Tucker. In Medscape                   

Les centres d'essais cliniques précoces contre le cancer
Comme tous les médicaments, les traitements contre le cancer doivent être évalués avoir de recevoir leur autorisation de mise sur le marché. Mais très souvent le temps presse pour les patients qui souhaitent bénéficier des techniques les plus avancées. C'est ainsi que sont nés les centres d'essais cliniques précoces.
Dans France Info

Traitements ciblés contre le cancer: l'eldorado risqué des grands labos
Proposer à des millions de patients des "traitements ciblés" en fonction de mutations génétiques retrouvées dans leur cancer, est devenu l'axe essentiel de la recherche pour les grands laboratoires, pari qui n'est pas sans risque vu le temps et les sommes colossales investis.
Par Olivier Thibault. Sur TV5

Aucun commentaire:

Enregistrer un commentaire